Loading…
AbCellera Biologics Inc. is projected to rise to $7.96 by 2027, a +17% move from its current price of $6.80. ABCL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $6.48 | $6.81 | $7.15 | +0.09% |
| Jul 14 | $6.36 | $6.81 | $7.30 | +0.18% |
| Jul 15 | $6.26 | $6.82 | $7.42 | +0.27% |
| Jul 16 | $6.19 | $6.82 | $7.53 | +0.36% |
| Jul 17 | $6.12 | $6.83 | $7.62 | +0.45% |
| Jul 18 | $6.06 | $6.84 | $7.71 | +0.54% |
| Jul 19 | $6.01 | $6.84 | $7.79 | +0.64% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.01 | $6.84 | $7.79 | +0.64% |
| Week 2 | $5.73 | $6.89 | $8.28 | +1.28% |
| Week 3 | $5.53 | $6.93 | $8.68 | +1.92% |
| Week 4 | $5.38 | $6.97 | $9.04 | +2.57% |
| Week 5 | $5.25 | $7.02 | $9.38 | +3.22% |
| Week 6 | $5.14 | $7.06 | $9.71 | +3.88% |
| Week 7 | $5.04 | $7.11 | $10.02 | +4.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AbCellera Biologics Inc. is a healthcare company focused on discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product ABCL635 is a non-hormonal medicine in Phase 2 clinical trials to treat moderate-to-severe vasomotor symptoms, and ABCL575 is a fully human, half-life extended monoclonal antibody in Phase 1 trials for treating T-cell-mediated autoimmune conditions such as atopic dermatitis.
The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging multispecific antibodies, and partnership agreements with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
ABCL is a healthcare stock trading at $7.10 with a market cap of $2.17B and a rank of 1977. The current price and market position provide context for near-term trading versus the longer-horizon forecast.
A major floor 51.9% below — a decisive break under it would weaken the trend.
The nearest floor, 25.1% below — buyers have tended to step in here.
The nearest ceiling, 19.4% above — a clean break opens room to run.
A major ceiling 42.6% above — clearing it would confirm fresh momentum.
Key ABCL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABCL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.35 | Sell | $7.22 | Sell |
| MA 10 | $7.58 | Sell | $7.19 | Sell |
| MA 20 | $6.58 | Buy | $6.79 | Buy |
| MA 50 | $5.68 | Buy | $5.87 | Buy |
| MA 100 | $4.62 | Buy | $5.13 | Buy |
| MA 200 | $4.45 | Buy | $4.57 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.12 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 14.28 | Neutral |
| Williams %R (14) | -53.01 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | 20.78 | Buy |
| Bollinger %B (20,2) | 0.55 | Neutral |
| Stochastic %K (14) | 46.99 | Neutral |
| TRIX (15) | 1.48 | Buy |
| Awesome (5,34) | 1.15 | Buy |
| Ultimate (7,14,28) | 41.52 | Neutral |
| Momentum (10) | 0.14 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 7.01 | Sell |
| ADX (14) | 24.89 | Buy |
| ATR (14) | 0.34 | Info |
The stock carries a BULLISH technical bias with RSI14 at 60. The chart shows the SMA50 at $5.56 and the SMA200 at $4.42, placing the price above both moving averages. This positioning supports a constructive near-term view.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.78 | $6.80 | $10.32 | 0% | Neutral | |
| $5.87 | $7.96 | $11.66 | +17% | Neutral | |
| $6.88 | $9.87 | $15.33 | +45% | Bullish | |
| $7.59 | $11.40 | $18.54 | +68% | Bullish | |
| $8.19 | $12.83 | $21.67 | +89% | Bullish | |
| $12.61 | $20.54 | $35.85 | +202% | Bullish | |
| $14.17 | $23.97 | $43.07 | +252% | Bullish | |
| $13.20 | $23.13 | $42.66 | +240% | Bullish | |
| $14.45 | $26.21 | $49.49 | +285% | Bullish | |
| $13.95 | $26.18 | $50.53 | +285% | Bullish | |
| $24.55 | $54.13 | $114.33 | +696% | Bullish | |
| $60.46 | $134.36 | $309.03 | +18.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.78 | $6.80 | $8.69 | +0.00% |
| August 2026 | $6.24 | $7.53 | $9.45 | +10.77% |
| September 2026 | $6.04 | $7.39 | $9.44 | -1.95% |
| October 2026 | $5.91 | $7.30 | $9.48 | -1.14% |
| November 2026 | $6.13 | $7.65 | $10.07 | +4.75% |
| December 2026 | $6.15 | $7.74 | $10.32 | +1.25% |
Click any year to see its month-by-month ABCL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ABCL price prediction for 2026 points to an average of $6.80 (low $2.78, high $10.32) — a potential gain of 0% on today's $6.80. A consolidation phase looks the most probable path here.
In 2027, ABCL is projected to trade between $5.87 and $11.66, averaging $7.96 — a potential gain of +17% from today's $6.80. That is up +17% on the projected 2026 average. Price action looks broadly range-bound.
AbCellera Biologics Inc.'s 2028 outlook centres on $9.87, within a $6.88 to $15.33 range. That is up +24% on the projected 2027 average. That marks a +45% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ABCL could reach as high as $18.54, with a base case around $11.40 and support toward $7.59 — roughly +68% from $6.80. Momentum favours further upside here.
Expect ABCL to range from $8.19 to $21.67 through 2030. The $12.83 average target implies a +89% move from current prices. That is up +13% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ABCL price prediction for 2031 points to an average of $20.54 (low $12.61, high $35.85) — a potential gain of +202% on today's $6.80. Momentum favours further upside here.
In 2032, ABCL is projected to trade between $14.17 and $43.07, averaging $23.97 — a potential gain of +252% from today's $6.80. That is up +17% on the projected 2031 average. Buyers look set to stay in control over this stretch.
AbCellera Biologics Inc.'s 2033 outlook centres on $23.13, within a $13.20 to $42.66 range. That is -3% versus the projected 2032 average. That marks a +240% change versus current levels. Momentum favours further upside here.
By 2034, ABCL could reach as high as $49.49, with a base case around $26.21 and support toward $14.45 — roughly +285% from $6.80. Buyers look set to stay in control over this stretch.
Expect ABCL to range from $13.95 to $50.53 through 2035. The $26.18 average target implies a +285% move from current prices. That is 0% versus the projected 2034 average. Momentum favours further upside here.
The ABCL price prediction for 2040 points to an average of $54.13 (low $24.55, high $114.33) — a potential gain of +696% on today's $6.80. Buyers look set to stay in control over this stretch.
In 2050, ABCL is projected to trade between $60.46 and $309.03, averaging $134.36 — a potential gain of +18.8x from today's $6.80. That is up +148% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ABCL today (≈ 147.058824 ABCL) could be worth
$19,758.91
+$18,758.91 (+1876%) by 2050 · US Dollar
Based on the average projected ABCL price of $134.36 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABCLwould be worth at today's price.
$1,000 invested in ABCL on Jul 10, 2025 (≈ 235.294118 ABCL) would be worth
$1,600
+$600 (+60.0%) today · 1.60× · US Dollar
Based on a ABCL entry price of $4.25 vs. today's $6.8.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.11 | $838.47 | -16.2% |
| 1 month ago | $5.09 | $1,335.95 | +33.6% |
| 3 months ago | $3.54 | $1,920.9 | +92.1% |
| 6 months ago | $4.52 | $1,504.42 | +50.4% |
| 1 year ago | $4.25 | $1,600 | +60.0% |
| All time (5.0y) ago | $17.83 | $381.38 | -61.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABCL forecast.
Our base-case forecast reaches $14.00 around 2031.
Implied market cap at $14.00: $4.28B
The multi-year forecast shows substantial upside, with the 2030 average price projected at $13.49 and a max of $22.87 (ROI 90, sentiment BULLISH). The 2040 forecast calls for an average of $54.66 and a max of $116.01 (ROI 669.9). By 2050, the average is projected to $136.43 and the max $313.80 (ROI 1821.6).
Tap a question to reveal the answer.
The 2030 forecast has an average price of $13.49, a min of $8.58, and a max of $22.87, with an ROI of 90% and a BULLISH sentiment.
Forecasts show rising average prices from 2026 onward, with bullish sentiment from 2027 through 2050 and a long-term average reaching $136.43 by 2050 (max $313.80). These estimates are not guarantees.
Yes. The 2040 max is $116.01 and the 2050 max is $313.80, indicating the potential to exceed $100 in the long term.
ABCL is currently $7.10 with a market cap of $2.17B.
Sentiment is BULLISH with RSI14 at 60. The SMA50 is $5.56 and the SMA200 is $4.42. Support is at $5.09 and resistance at $8.12. The 30-day range is $5.12 to $9.85.
AbCellera Biologics Inc. Community Discussion
0Share your AbCellera Biologics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.